...
首页> 外文期刊>Acta Medica Academica >Prognostic factors of overall survival for patients with stage II colon cancer
【24h】

Prognostic factors of overall survival for patients with stage II colon cancer

机译:II期结肠癌患者总体生存的预后因素

获取原文

摘要

Objective. To analyze factors influencing survival of patients with stage II colon cancer treated at our cancer center (Sparrow Hospital) from February 1996 through December 2006. Patients and methods. Survival analyses on 197 patients’ age 71.1±0.9 years (29 to 97) were done using SAS system (V9.3, Cary NC). Analysis included age, gender, stage, surgery type, number of examined lymph nodes, pathological grade, tumor size and the use of adjuvant chemotherapy. Results. Mean follow up length was 48.1±2.3 months (0.1-133) and 56±3.3 (0.2-133) for survivors. The average number of removed lymph nodes was 18±13 (1-103). Adjuvant chemotherapy treatment (5-FU± leucovorin) was given to 49 patients, while others (148) were followed expectantly. There were 90 deaths during follow up. Only age exhibits a statistically significant relationship to survival (Hazard Ratio (HR) =1.06, 95% CI=1.03-1.08, p<0.001). Adjuvant chemotherapy possibly reduced the risk of death by 42% approaching a borderline advantage for survival (HR=0.58, CI=0.33-1.03, p=0.06. The number of removed lymph nodes also showed a possible relationship to survival (HR=0.98, CI= 0.62-1.56, p=0.07). Other investigated factors (gender, type of surgery, etc.) were not significant correlates. Conclusion. In this study we found that the most important factor for survival of patients with Stage II colon cancer is the patient’s age. Adjuvant chemotherapy showed a borderline significance while the number of resected lymph nodes seemed to be an important survival factor. However, in our study statistical significance was not achieved.
机译:目的。分析从1996年2月至2006年12月在我们癌症中心(麻雀医院)治疗的II期结肠癌患者生存的影响因素。患者和方法。使用SAS系统(V9.3,Cary NC)对197例71.1±0.9岁(29至97岁)的患者进行了生存分析。分析包括年龄,性别,分期,手术类型,检查的淋巴结数目,病理等级,肿瘤大小和辅助化疗的使用。结果。幸存者的平均随访时间为48.1±2.3个月(0.1-133)和56±3.3(0.2-133)。切除的淋巴结平均数量为18±13(1-103)。对49例患者进行了辅助化疗治疗(5-FU±亚叶酸),其他患者(148例)接受了随访。随访期间有90人死亡。只有年龄与存活率具有统计学上的显着关系(危险比(HR)= 1.06,95%CI = 1.03-1.08,p <0.001)。辅助化疗可能将死亡风险降低42%,接近生存的优势(HR = 0.58,CI = 0.33-1.03,p = 0.06。切除的淋巴结数目也显示出与生存的可能关系(HR = 0.98, CI = 0.62-1.56,p = 0.07)。其他调查因素(性别,手术类型等)无显着相关性结论:本研究发现,II期结肠癌患者生存的最重要因素辅助化疗显示出临界意义,而切除的淋巴结数目似乎是重要的生存因素,但是,在我们的研究中并未达到统计学意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号